Inventor · disambiguated record
Bernhard Hubert Geierstanger
Also filed as: GEIERSTANGER BERNHARD · GEIERSTANGER BERNHARD H · GEIERSTANGER BERNHARD HUBERT
20 granted patents·16 pending applications·73 citations·filing 2003–2024
92Inventor score
Files withNOVARTIS AG16GEIERSTANGER BERNHARD HUBERT5BOETTCHER BRIAN R3NOVARTS AG3GEIERSTANGER BERNHARD2
Top patents by PatentIndex Score
36 records- 0193US9023791B2Fibroblast growth factor 21 mutationsBOETTCHER BRIAN R·Filed 2011·Granted May 5, 2015·37 cites·39 claims
- 0289US10786578B2CKIT antibody drug conjugatesNOVARTIS AG·Filed 2015·Granted Sep 29, 2020·4 cites·12 claims
- 0388US12171839B2Antibody drug conjugates for ablating hematopoietic stem cellsNOVARTIS AG·Filed 2022·Granted Dec 24, 2024·1 cites·11 claims
- 0488US11634497B2Anti-CCR7 antibody drug conjugatesNOVARTIS AG·Filed 2018·Granted Apr 25, 2023·5 cites·26 claims
- 0588US10669323B2Methods of treating metabolic disorders with dual function fibroblast growth factor 21 proteinsBOETTCHER BRIAN R·Filed 2016·Granted Jun 2, 2020·5 cites·15 claims
- 0686US10787480B2Cytotoxic peptides and conjugates thereofNOVARTIS AG·Filed 2019·Granted Sep 29, 2020·2 cites·11 claims
- 0784US10973826B2Antibody conjugates comprising toll-like receptor agonistCORTEZ ALEX·Filed 2016·Granted Apr 13, 2021·6 cites·28 claims
- 0882US11596695B2Specific sites for modifying antibodies to make immunoconjugatesNOVARTIS AG·Filed 2019·Granted Mar 7, 2023·1 cites·18 claims
- 0982US10392421B2Cytotoxic peptides and conjugates thereofNOVARTIS AG·Filed 2018·Granted Aug 27, 2019·3 cites·12 claims
- 1081US9884817B2Auristatin derivatives and conjugates thereofGEIERSTANGER BERNHARD HUBERT·Filed 2015·Granted Feb 6, 2018·4 cites·17 claims
- 1179US2025064964A1Antibody drug conjugates for ablating hematopoietic stem cellsNOVARTIS AG·Filed 2024·Application pending·0 cites
- 1278US9988420B2Cytotoxic peptides and conjugates thereofGEIERSTANGER BERNHARD HUBERT·Filed 2014·Granted Jun 5, 2018·4 cites·29 claims
- 1376US2023270876A1Specific sites for modifying antibodies to make immunoconjugatesNOVARTIS AG·Filed 2023·Application pending·0 cites
- 1469US12180291B2Anti-CCR7 antibody drug conjugatesNOVARTIS AG·Filed 2023·Granted Dec 31, 2024·0 cites·17 claims
- 1565US9624520B2Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residuesGEIERSTANGER BERNHARD·Filed 2014·Granted Apr 18, 2017·1 cites·7 claims
- 1662US2021346387A1Antibody conjugates comprising toll-like receptor agonistNOVARTIS AG·Filed 2021·Application pending·0 cites
- 1761US2022127321A1Antibody cytokine engrafted compositions and methods of use for immunoregulationNOVARTS AG·Filed 2021·Application pending·0 cites
- 1860US11833215B2CKIT antibody drug conjugatesNOVARTIS AG·Filed 2020·Granted Dec 5, 2023·0 cites·17 claims
- 1959US2025382355A1Polypeptides effective against multiple coronavirusesMERCK SHARP & DOHME LLC·Filed 2023·Application pending·0 cites
- 2057US11357864B2Antibody drug conjugates for ablating hematopoietic stem cellsNOVARTIS AG·Filed 2017·Granted Jun 14, 2022·0 cites·23 claims
- 2157US9585970B2Site-specific labeling methods and molecules produced therebyGEIERSTANGER BERNHARD HUBERT·Filed 2013·Granted Mar 7, 2017·0 cites·6 claims
- 2255US2016067351A1Specific sites for modifying antibodies to make immunoconjugatesGEIERSTANGER BERNHARD HUBERT·Filed 2014·Application pending·0 cites
- 2355US2008171317A1Site-Specific Labeling of Proteins for Nmr StudiesSCRIPPS RESEARCH INST·Filed 2005·Application pending·0 cites
- 2454US8785151B2Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residuesGEIERSTANGER BERNHARD·Filed 2009·Granted Jul 22, 2014·0 cites·7 claims
- 2552US11136366B2Methods of treating immune related disorders using antibody-cytokine engrafted compositionsNOVARTS AG·Filed 2018·Granted Oct 5, 2021·0 cites·12 claims
- 2650US2021228731A1Antibody drug conjugates for ablating hematopoietic stem cellsNOVARTIS AG·Filed 2019·Application pending·0 cites
- 2750US2009081690A1Site-specific labeling of proteins for NMR studiesSCRIPPS RES INST AND IRM LLC·Filed 2008·Application pending·0 cites
- 2849US10280139B2Cytotoxic peptides and conjugates thereofNOVARTIS AG·Filed 2017·Granted May 7, 2019·0 cites·20 claims
- 2948US2017218085A1Site-specific labeling methods and molecules produced therebyGEIERSTANGER BERNHARD HUBERT·Filed 2017·Application pending·0 cites
- 3047US10144768B2Antibody cytokine engrafted compositions and methods of use for immunoregulationNOVARTS AG·Filed 2016·Granted Dec 4, 2018·0 cites·8 claims
- 3147US2004141887A1Apparatus and methods to process substrate surface featuresIRM LLC·Filed 2003·Application pending·0 cites
- 3246US2006110784A1Site-specific labeling of proteins for NMR studiesIRM LLC·Filed 2005·Application pending·0 cites
- 3341US2020164084A1Antibody conjugates comprising toll-like receptor agonist and combination therapiesNOVARTIS AG·Filed 2018·Application pending·0 cites
- 3439US2016051628A1Methods of treating fgf21-associated disordersBOETTCHER BRIAN R·Filed 2015·Application pending·0 cites
- 3539US2019194315A1Antibody drug conjugatesABRAMS TINYA·Filed 2016·Application pending·0 cites
- 3636US2017021033A1Specific sites for modifying antibodies to make immunoconjugatesNOVARTIS AG·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →